Ankündigung • May 23
Seegene Launches Allplex MDRO Assay Under IVDR Seegene announced the European launch of its new antimicrobial resistance (AMR) testing product, Allplex MDRO Assay, which is CE marked under the EU In Vitro Diagnostic Regulation (IVDR). The assay is designed to support the detection of multidrug-resistant organisms (MDROs) associated with healthcare-associated infections (HAIs). The assay is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run, enabling rapid simultaneous detection across a broader range of MDRO targets. It also supports rapid first-line screening before the availability of culture-based results, helping enable timely infection prevention and control (IPC) responses in hospital settings. The launch reflects Seegene's strategy to expand its AMR testing capabilities in response to evolving infectious disease trends. As antimicrobial resistance continues to rise globally, the burden of healthcare-associated infections is increasing, driving demand for faster and more comprehensive diagnostic approaches. Public health agencies, including the U.S. Centers for Disease Control and Prevention (CDC), have continued to emphasize the importance of strengthened infection surveillance and control capabilities in healthcare settings. The Allplex MDRO Assay complements Seegene's existing Allplex Entero-DR Assay, enabling a combined testing approach that covers both antimicrobial-resistant enteric bacteria and additional high-risk MDRO targets. This combined approach can support broader infection-control efforts against antimicrobial-resistant organisms, while strengthening Seegene's overall AMR testing portfolio. The assay enables simultaneous detection of multiple resistance genes and can support same-day reporting depending on laboratory workflow. This can provide timely information to support infection-control responses and complement conventional culture-based workflows. It may also help support more efficient laboratory workflows in appropriate clinical settings. Seegene plans to further strengthen its diagnostic capabilities for healthcare-associated infections and advance its strategy in line with growing demand for enhanced infection surveillance and control. Product availability may vary by country and is subject to local regulatory requirements. The company is also developing the Allplex MRSA Assay for detection of methicillin-resistant Staphylococcus aureus (MRSA), which is targeted for launch next year as part of its broader AMR testing portfolio expansion strategy. Major Estimate Revision • May 14
Consensus EPS estimates increase by 52%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩532.0m to ₩517.8m. EPS estimate rose from ₩1,116 to ₩1,697. Net income forecast to grow 84% next year vs 27% growth forecast for Biotechs industry in South Korea. Consensus price target of ₩39,500 unchanged from last update. Share price rose 33% to ₩32,000 over the past week. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩28,250, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Biotechs industry in South Korea. Total returns to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩53,224 per share. Reported Earnings • Mar 24
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: ₩1,047 (up from ₩190 loss in FY 2024). Revenue: ₩474.2b (up 14% from FY 2024). Net income: ₩48.3b (up ₩57.0b from FY 2024). Profit margin: 10% (up from net loss in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 13
Seegene, Inc., Annual General Meeting, Mar 27, 2026 Seegene, Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 5, baekjegobun-ro 42-gil, songpa-gu, seoul South Korea Price Target Changed • Mar 03
Price target decreased by 8.1% to ₩39,500 Down from ₩43,000, the current price target is an average from 2 analysts. New target price is 56% above last closing price of ₩25,250. Stock is up 4.3% over the past year. The company is forecast to post earnings per share of ₩1,098 next year compared to a net loss per share of ₩441 last year. Ankündigung • Feb 20
Seegene, Inc. to Report Q4, 2025 Results on Feb 25, 2026 Seegene, Inc. announced that they will report Q4, 2025 results on Feb 25, 2026 Upcoming Dividend • Dec 22
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 27 April 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.3%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Major Estimate Revision • Aug 15
Consensus EPS estimates fall by 34% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩1,547 to ₩1,021 per share. Revenue forecast steady at ₩482.1m. Net income forecast to grow 486% next year vs 58% growth forecast for Biotechs industry in South Korea. Consensus price target reaffirmed at ₩43,000. Share price fell 7.2% to ₩27,900 over the past week. Ankündigung • Aug 08
Seegene Inc. Unveils CURECA™? and STAgora™? At ADLM 2025, Advancing the Next Stage of Diagnostics Seegene Inc. unveiled two new technologies at ADLM 2025 in Chicago (July 29-31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™?, world's first fully unattended PCR automation system, and STAgora™?, a real-time data analytics platform intended to support earlier detection and precision care. most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™? is designed to meet all three. Its dedicated module, CURECA™? Prep, processes a wide range of specimen types such as urine, blood, sputum, andool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™? system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™? are intended to help laboratories overcome these challenges by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™? Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™? is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™? is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™? are designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Upcoming Dividend • Jun 20
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 27 August 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Price Target Changed • May 18
Price target increased by 8.9% to ₩43,000 Up from ₩39,500, the current price target is an average from 2 analysts. New target price is 39% above last closing price of ₩30,950. Stock is up 39% over the past year. The company is forecast to post earnings per share of ₩1,547 next year compared to a net loss per share of ₩441 last year. Ankündigung • Apr 09
Seegene Inc. Announces Development of CURECA, A Next-Generation Fully Automated PCR Solution Featuring Customizable Pre- Treatment Automation Seegene Inc. is advancing its vision for innovation in laboratory automation with the development of CURECA™? -- a next-generation system currently under development, designed to streamline automation in Polymerase Chainaction (PCR) testing and laboratory environments. The company announced that it will showcase a conceptual video introducing the CURECA™? system at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), held April 11-15 in Vienna, Austria. The video will outline the system's design goals and envisioned workflow. A physical demonstration of the system is expected to take place in July 2025 at the Association for Diagnostics & Laboratory Medicine (ADLM 2025) in Chicago. CURECA™? -- short for Continuous Unlimited Random access Expandable and Customizable full Automation -- is Seegene's envisioned PCR testing solution, intended to enable full automation of the PCR testing workflow. The system is expected to include two core components: the Customizable Pre-treatment System (CPS), responsible for sample loading and pre-treatment processing; and Customizable and Expandable Full Automation (CEFA), which would carry out sample loading and preparation for nucleic acid extraction, PCR setup, gene amplification, and result analysis. The pre-treatment stage in MDx requires careful handling of various specimen types -- such as stool, urine, blood, and sputum -- as well as sorting different container formats. Traditionally, this process has relied heavily on manual labor by trained laboratory professionals. Seegene aims to lead innovation in automating pre-treatment processing for all PCR specimen types through the development of CPS. The system is designed to automate key steps such as sample sorting, centrifugation,ortexing and heat treatment. CPS may also operate independently of the full CURECA™? system and be applied to other laboratory testing areas such as hematology, biochemistry, and immunodiagnostics -- broadening its potential utility in clinical laboratory workflows. The modular design of CURECA™? is intended to provide laboratories with flexibility to configure the system according to their operational needs. By supporting automation across the full workflow, the system aims to help reduce the risk of human error and enable continuous, high-throughput PCR testing 24 hours a day, seven days a week. At ESCMID Global 2025, Seegene will present a conceptual video simulating the full PCR automation workflow -- from sample loading and pre-treatment Processing to nucleic acid extraction, PCR structure, gene amplification, and result analyses. The presentation will further highlight the system's adaptability across different laboratory environments and testing capacities. Ankündigung • Mar 13
Seegene, Inc., Annual General Meeting, Mar 28, 2025 Seegene, Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 91, ogeum-ro, songpa-gu, seoul South Korea New Risk • Feb 27
New major risk - Revenue and earnings growth Earnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (219% payout ratio). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩27,850, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 47% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 3.4%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%). New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023) Third quarter 2024 results: EPS: ₩36.00 (up from ₩101 loss in 3Q 2023). Revenue: ₩108.8b (up 18% from 3Q 2023). Net income: ₩1.67b (up ₩6.34b from 3Q 2023). Profit margin: 1.5% (up from net loss in 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Ankündigung • Sep 23
Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD) Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD) Upcoming Dividend • Sep 20
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 28 November 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 3.1%. Lower than top quartile of South Korean dividend payers (3.8%). Higher than average of industry peers (0.5%). Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩25,950, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,843 per share. Ankündigung • Aug 26
Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration Seegene, Inc. announced that it has developed its PCR test assays in response to the public health emergency of international concern (PHEIC) declared by the World Health Organization's (WHO) on the global spread of mpox. The products, which are intended for research use only (RUO), include Novaplex™ MPXV/OPXV Assay (RUO) and Novaplex™ HSV-1&2/VZV/MPXV Assay (RUO). In particular, Novaplex™ HSV-1&2/VZV/MPXV Assay (RUO) is designed to detect four viruses including mpox virus and other key STI-causing pathogens. Seegene previously developed Novaplex MPXV (RUO) in 2022 using its advanced Seegene Digitalized Development System (SGDDS), which was developed based on Seegene's expertise to rapidly create and deploy new assays. There are growing calls to ensure access to medicines for developing countries as mpox, once an endemic disease in Africa, poses a global threat. Seegene's development of assays aims to curb the global outbreak of mpox and advance its vision of a "world free from all diseases." NovaplexTM MPXV/OPXV Assay (RUO) is designed to detect pathogens caused by Orthopox-viruses, including Clades 1 and 2 of the mpox virus. It enables early differentiation of mpox, which has a long incubation period of up to 21 days. NovaplexTM HSV-1&2/VZV/MPXV Assay (RUO) is designed to detect Clade 1 and Clade 2 of the mpox virus, while also distinguishing between Clade 2 of the mpox virus. If the test results are negative for Clade 2, researchers can infer the presence of Clade 1. This assay provides reliable test results with broad coverage, detecting type 1 and type 2 of herpes simplex virus (HSV), as well as varicella-zoster virus (VZV) that exhibit symptoms similar to the mpox virus using the multiplex PCR testing. Both assays feature dual internal controls (Endogenous Internal Control, Exogenous Internal Control) within the same tube. These controls validate the integrity of the sample and verify the entire testing process, ensuring highly reliable results. New Risk • Aug 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (11% average weekly change). Buy Or Sell Opportunity • Aug 05
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 2.9% to ₩22,800. The fair value is estimated to be ₩17,763, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 48% over the last 3 years. Meanwhile, the company became loss making. Upcoming Dividend • Jun 20
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 27 June 2024. Payment date: 29 August 2024. The company is not currently making a profit and its cash payout ratio is 87%. Trailing yield: 3.8%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.6%). Buy Or Sell Opportunity • May 10
Now 20% overvalued Over the last 90 days, the stock has fallen 16% to ₩22,600. The fair value is estimated to be ₩18,797, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 38% over the last 3 years. Earnings per share has declined by 73%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 7,179% in the next 2 years. Upcoming Dividend • Mar 21
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 30 May 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.1%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.5%). Reported Earnings • Mar 19
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: ₩14.00 (down from ₩3,586 in FY 2022). Revenue: ₩367.4b (down 57% from FY 2022). Net income: ₩669.0m (down 100% from FY 2022). Profit margin: 0.2% (down from 21% in FY 2022). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. New Risk • Jan 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (9.6% average weekly change). Buy Or Sell Opportunity • Jan 29
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 52% to ₩29,000. The fair value is estimated to be ₩22,744, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Meanwhile, the company became loss making. Upcoming Dividend • Dec 20
Upcoming dividend of ₩200 per share at 3.5% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 3.5%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%). Price Target Changed • Oct 03
Price target decreased by 8.8% to ₩25,000 Down from ₩27,400, the current price target is provided by 1 analyst. New target price is 17% above last closing price of ₩21,350. Stock is down 22% over the past year. The company is forecast to post a net loss per share of ₩18.00 compared to earnings per share of ₩3,586 last year. New Risk • Oct 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 97% Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Upcoming Dividend • Sep 19
Upcoming dividend of ₩200 per share at 3.7% yield Eligible shareholders must have bought the stock before 26 September 2023. Payment date: 28 November 2023. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.4%). Higher than average of industry peers (0.7%). Major Estimate Revision • Aug 19
Consensus EPS estimates fall from profit to ₩18.00 loss The consensus outlook for fiscal year 2023 has been updated. Expected to report loss instead of -₩18.00 instead of ₩329 per share profit previously forecast. Revenue forecast unchanged at ₩354.3m Biotechs industry in South Korea expected to see average net income growth of 21% next year. Consensus price target broadly unchanged at ₩27,000. Share price fell 5.6% to ₩20,900 over the past week. New Risk • Aug 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 267% Cash payout ratio: 110% Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin). Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩25,300, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 37x in the Biotechs industry in South Korea. Total loss to shareholders of 83% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩15,648 per share. Ankündigung • Aug 01
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC Seegene Inc. took part in the 2023 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in California between July 25-27. Segene showcased its " unique syndromic quantitative PCR assays and automated PCR solution 'STARlet AIOS™? (All-in-One System). Meanwhile, an in-depth discussion was conducted in the symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases. This symposium reaffirmed Seegene's position as an important contributor to improving gastrointestinal testing, where the availability of skilled technicians for microscopy is decreasing. A panel of experts presented research results demonstrating that PCR testing provides more efficient and accurate results than traditional microscopic stool sample tests for diagnosing gastrointestinal diseases. Conventional testing methods for these pathogens are characterized by long processing times and require significant expertise to interpret the microscopy results. In addition, Kim Seong-youl, the head of Seegene's Global Marketing Center, participated in a presentation event for major Korean in-vitro diagnostic companies organized by the Korea Health Industry Development Institute (KHIDI) and announced Seegene's unique competitive edge and future vision. Using syndromic quantitative PCR assay for comprehensive and accurate testing: Seegene captivated visitors at the exhibition booth by showcasing comprehensive and accurate testing using syndromic quantitative PCR assayed. As it provides a ' hands-free' PCR workflow where the results are produced just by inserting a sample, it can be operated by those with minimal PCR experience. Furthermore, by not involving human hands, the likelihood of testing errors due to contamination or mistakes (human error) can be minimized. The STARlet AIOS™? is compatible with a wide range of Seegene's syndromic assays that can simultaneously test for multiple targets within a single tube. It organically links existing devices, such as nucleic acid extraction instruments, PCR setups, and PCR thermal cyclers, to make the system easy to use, manage, and integrate into existing lab infrastructures. Participants in the world's world's world's only simultaneous multiplex molecular diagnostic technology based on real-time PCR. The core feature of Seegene's syndro PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with the severity of illness. The syndromic quantitative PCR technology can accurately reveal the pathogen responsible for a patient's symptoms, the complexity of infections, the severity of infection, and can determine the priority of treatment depending on the degree of infection. It also allows for efficient high-volume testing, which is more cost-effective and saves time in identifying the cause of the disease. PCR testing that does not require an expert using STARlet AIOS™?. First unveiled at the 2021 AACC, Seegene's STARlet AIOS™? are a molecular diagnostic testing system that fully automated (sample in - result out) the entire process of PCR, from nucleic acid extraction to gene amplification and result analysis. As it provides a 'hands-free' PCR workflow where The results are produced just by inserting an sample, it can be operated By-free PCR workflow where the results are produce just by inserting a sample, It can be operated by those with minimum PCR experience. Furthermore, by Not involving human hands, the likelihood to testing errors due to contamination or errors (human error) can be minimize. The STARlet AIOS®? is compatible with a wide wide range of Seegene' syndromic assays that will simultaneously test for multiple targets within an single tube. It organically link existing devices, such as nucleIC acid extraction instruments, PCR setups and PCR thermal cyclers, To make the system easy to use and integrate into existing lab inf infrastructures. Participants of the world's world's global lab infrastructures. Ankündigung • Jul 14
Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares. Seegene, Inc. (KOSDAQ:A096530) announces a share repurchase program. Under the program, the company will repurchase up to KRW 30,000 million worth of its shares pursuant to the contract with Samsung Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on July 15, 2024. As of July 12, 2023, the company had 5,618,778 and 5,195 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively. Upcoming Dividend • Jun 22
Upcoming dividend of ₩200 per share at 3.7% yield Eligible shareholders must have bought the stock before 29 June 2023. Payment date: 29 August 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.2%). Higher than average of industry peers (0.6%). Upcoming Dividend • Mar 23
Upcoming dividend of ₩200 per share at 3.1% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 02 June 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%). Reported Earnings • Mar 22
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₩3,586 (down from ₩10,359 in FY 2021). Revenue: ₩853.6b (down 38% from FY 2021). Net income: ₩182.1b (down 66% from FY 2021). Profit margin: 21% (down from 39% in FY 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 10%. Revenue is expected to decline by 29% p.a. on average during the next 2 years, while revenues in the Biotechs industry in South Korea are expected to grow by 10%. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Major Estimate Revision • Feb 22
Consensus revenue estimates fall by 21% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩558.7m to ₩440.0m. EPS estimate fell from ₩2,245 to ₩1,002 per share. Net income forecast to shrink 73% next year vs 29% growth forecast for Biotechs industry in South Korea . Consensus price target down from ₩36,000 to ₩32,667. Share price was steady at ₩26,200 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 3.6%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩28,100, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Biotechs industry in South Korea. Total returns to shareholders of 115% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩19,309 per share. Price Target Changed • Nov 22
Price target decreased to ₩38,667 Down from ₩42,200, the current price target is an average from 3 analysts. New target price is 20% above last closing price of ₩32,100. Stock is down 49% over the past year. The company is forecast to post earnings per share of ₩3,917 for next year compared to ₩10,359 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Sep 29
Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares. Seegene, Inc. (KOSDAQ:A096530) announces a share repurchase program. Under the program, the company will repurchase up to $50,000 million worth of its shares according to the contract with SAMSUNG SECURITIES CO., LTD. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on March 28, 2023. As of September 27, 2022, the company had 1,791,816 and 5,195 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively. Upcoming Dividend • Sep 22
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 3.8%. Within top quartile of South Korean dividend payers (3.1%). Higher than average of industry peers (0.7%). Major Estimate Revision • Aug 18
Consensus revenue estimates fall by 24% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from ₩1.13b to ₩866.5m. EPS estimate fell from ₩7,105 to ₩4,697 per share. Net income forecast to shrink 56% next year vs 7.7% growth forecast for Biotechs industry in South Korea . Consensus price target down from ₩55,667 to ₩47,700. Share price fell 12% to ₩34,700 over the past week. Buying Opportunity • Aug 10
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₩48,881, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 76% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to decline by 52% in 2 years. Earnings is forecast to decline by 66% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 20% share price gain to ₩43,250, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 245% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩46,579 per share. Ankündigung • Jun 29
Seegene Inc. Develops PCR Test to Detect Monkeypox Virus Seegene Inc. announced that it has developed a PCR test to detect the monkeypox virus. The Novaplex™ MPXV Assay, which specifically targets the monkeypox virus, was swiftly developed using the company's AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), and technologies refined over 20 years of MDx expertise. As with many infectious diseases, accurate diagnosis is crucial as treatments are more effective in the early stages of infection. This makes timely PCR testing vital, especially for individuals with a suspected case, as the incubation period for the monkeypox infection ranges between five to 21 days. The Novaplex™ MPXV Assay can identify positive cases of the monkeypox virus in 90 minutes. The company swiftly developed the product to help curb the worldwide spread. Seegene plans to provide the assays to countries that have detected the virus. Upcoming Dividend • Jun 22
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 29 June 2022. Payment date: 03 August 2022. Payout ratio is a comfortable 9.6% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of South Korean dividend payers (3.2%). Higher than average of industry peers (0.7%). Buying Opportunity • Jun 13
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be ₩52,625, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 76% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to decline by 52% in 2 years. Earnings is forecast to decline by 66% in the next 2 years. Price Target Changed • May 18
Price target decreased to ₩71,500 Down from ₩81,500, the current price target is an average from 2 analysts. New target price is 77% above last closing price of ₩40,500. Stock is down 49% over the past year. The company is forecast to post earnings per share of ₩7,565 for next year compared to ₩10,359 last year. Ankündigung • Apr 27
Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay Seegene, Inc. announced the development of the world's first commercialized PCR assay applying '3 Ct' technology. The 'Allplex™ HPV HR Detection' was showcased at the 2022 European Congress of Clinical Microbiology and Infectious Diseases held April 23-26 in Lisbon, Portugal. In a polymerase chain reaction, the cycle threshold value is used to quantify the concentration of a viral DNA sequence . Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel. But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity. The successful development is based on Seegene's 20-year expertise and combines 19 different patented technologies, including DPO™, TOCE™, and MuDT™. Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets. '3 Ct' has been dubbed the "dream MDx technology." The company plans to apply '3 Ct' technology to its entire product line-up, including respiratory virus, sexually transmitted infection, gastrointestinal infection, and urinary tract infection assays. Seegene expects '3 Ct' technology to take syndromic testing to another level. By detecting the causative pathogen, level of infection, and potential of co-infection, it will help determine the priority of treatment and enhance patient management. '3 Ct' technology also increases testing capacity. Such features are expected to improve the service and cost-structure of the medical sector once '3 Ct' technology is widely utilized. Seegene's first '3 Ct' technology applied product, Allplex™ HPV HR Detection, is designed to detect 14 high-risk human papillomavirus types that can cause cervical cancer . It also provides the individual Ct value of each of the types allowing quantitative analysis regarding infection level. Early detection of HPV contributes to the prevention and management of cervical cancer. HPV products from other industry players provide individual Ct values for two high-risk types, HPV 16 and 18. The Allplex™ HPV HR Detection, planned to be launched within the first half of this year, will come with a significant cost advantage compared to existing HPV products to increase accessibility to PCR testing, which had been difficult previously due to high costs. The product will also be compatible with Seegene's fully automated AIOS . The company plans to introduce the industry's first 'fully automated, mass, syndromic testing system,' to lay the foundation for testing anywhere, including large hospitals, C-Labs, and even small and medium-sized clinics, and make PCR testing part of everyday life. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩41,600, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 257% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩56,467 per share. Buying Opportunity • Apr 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 25%. The fair value is estimated to be ₩56,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Earnings per share has grown by 92%. Revenue is forecast to decline by 30% in 2 years. Earnings is forecast to decline by 43% in the next 2 years. Ankündigung • Apr 07
Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval Seegene Inc. announced that its Allplex™ RV Master Assay has received approval from Australia's Therapeutic Goods Administration. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country. The company's Allplex™ RV Master Assay can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds. Specifically, the assay can identify three genes of COVID-19, Flu A, Flu B, metapneumovirus, two types of respiratory syncytial virus, four types of parainfluenza virus, six types of adenovirus and three types of human rhinovirus. The Allplex™ RV Master Assay was developed based on the company's decades-long know-how and applies patent technologies, like DPO™, TOCE™ and MuDT™. The syndromic test allows medical specialists to swiftly find out which viruses are making the patient sick with a single sample. The company's independent clinical test recently conducted in Europe using the Allplex™ RV Master Assay on 1,928 people also found that 16.5% (318 people) tested positive for respiratory viruses, excluding COVID-19. Of that figure, 6.9% (22 people) had contracted two or more viruses. Reported Earnings • Mar 11
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: ₩10,359 (up from ₩9,662 in FY 2020). Revenue: ₩1.37t (up 22% from FY 2020). Net income: ₩536.6b (up 6.8% from FY 2020). Profit margin: 39% (down from 45% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 3.6% compared to a 55% growth forecast for the pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 25
Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era Seegene Inc. announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and cost-efficient testing is vital. The test can deliver results within 30 minutes, the fastest among diagnostics assays developed by Seegene, while matching the accuracy of RT-PCR tests. Thanks to its cost efficiency, the assay is expected to allow wide-spread access and can be easily used at airports, schools and other large-scale facilities. Faster Turnaround Times: The new test uses an isothermal amplification method that does not require a thermal cycler used during the amplification process, thereby reducing the turnaround time. Seegene advanced the isothermal amplification method by utilizing its AI-based assay design system, to specifically target the genes of SARS-CoV-2. By combining such method and Seegene's applied TOCE™ technology, Allplex™ SARS-CoV-2 fast MDx Assay delivers highly accurate results within 30 minutes. Greater Testing Capacity: Faster turnaround times lead to greater lab testing capacity of up to five times with existing Seegene's PCR instruments. Increased testing is critical as countries ease Covid-19 restrictions. Mass testing can be the most effective tool for large-scale events and venues such as concerts, airports, schools and stadiums. High Accuracy: The assay can deliver accurate results near RT-PCR tests, even detecting COVID-19 viruses from asymptomatic patients. In a recent experiment, Seegene's new assay results agreed with positive results generated through conventional RT-PCR. Rapid antigen tests have been the go-to solution for timely, point-of-care testing. However, its accuracy has been questioned as, in some cases, it can give false-negative results, especially for transmissible but asymptomatic patients. In the coming months, Seegene will allow laboratories to process Allplex™ SARS-CoV-2 fast MDx Assay using its fully automated MDx system, AIOS. The combination of these two will offer a 'hands-free' workflow from extraction to the interpretation of results without manual intervention. This will increase the access to testing at venues where they need fast, accurate and large-scale testing. This assay's price will also be more economical than standard RT-PCR assays. Major Estimate Revision • Feb 21
Consensus revenue estimates increase by 13% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from ₩1.17b to ₩1.32b. EPS estimate increased from ₩7,682 to ₩8,799 per share. Net income forecast to shrink 14% next year vs 4.4% growth forecast for Biotechs industry in South Korea . Consensus price target of ₩81,500 unchanged from last update. Share price rose 6.7% to ₩51,800 over the past week. Major Estimate Revision • Jan 26
Consensus revenue estimates increase by 10% The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from ₩1.26b to ₩1.39b. EPS estimate increased from ₩8,892 to ₩10,333 per share. Net income forecast to shrink 22% next year vs 9.8% growth forecast for Biotechs industry in South Korea . Consensus price target up from ₩79,000 to ₩81,500. Share price rose 3.5% to ₩56,100 over the past week. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment improved over the past week After last week's 16% share price gain to ₩62,800, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 616% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩34,771 per share. Ankündigung • Jan 20
Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing Seegene Inc. announced the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is expected to reduce the total turnaround time to a third and expand testing capacity up to 3 times for hospitals and laboratories without additional instruments or compromise on accuracy. Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half. 2) Seegene's innovative extraction-free method, which can let Allplex™ SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests. This drastically reduces the total turnaround time for each result. As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour. The Allplex™ SARS-CoV-2 Fast PCR Assay targets three COVID-19 genes––E, RdRP, and N–– to reliably detect COVID-19 regardless of the variants. According to clinical research conducted by 17 laboratories in seven countries, this assay showed the same or better accuracy for the COVID-19 detection as other diagnostic tests available in the market. Ankündigung • Jan 18
Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order Seegene Inc. announced it has received approval of its Allplex SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order on January 11. Seegene's Allplex SARS CoV-2 FluA/FluB/RSV Assay is a multiplex real-time PCR assay that enables simultaneous amplification and differentiation of respiratory symptoms. In a single test, it can distinguish among Influenza A, B, RSV, and COVID-19. This assay expected to play a crucial role in responding against the potential 'twindemic' as the country is forecasting a surge in both flu patients and COVID-19 patients. To support Canada experiencing surging demand for COVID-19 tests, Seegene delivered 340,000 COVID-19 tests to Canada by a charter flight on January 13. Ankündigung • Dec 10
Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape Seegene Inc. unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron and its stealth version, as well as other variants. The company believes the new PCR test will be effective in helping governments and health authorities to fight current variants. Immediately after the World Health Organization (WHO) announced a discovery of the Omicron variant, the company implemented its AI-based in-silico system to conclude this development within a week. In a single tube, the new RT-PCR test targets a total of five analytes including the RdRP gene, which confirms positive COVID-19 cases, and three key Omicron S-gene mutations: E484A, N501Y, HV69/70 deletion. And it also targets Endo IC, which serves as a control to verify specimen validity. The assay was validated using variable nucleic acid of COVID-19 samples including Alpha, Beta, Gamma, Delta, and Omicron cases. This latest test can differentiate between the Omicron variant and its 'stealth' version. The newly emerging stealth version lacks certain features (HV69/70 deletion) that are being targeted by other PCR tests to identify the Omicron variant. Company's proprietary mTOCE technology makes it possible to target multiple genetic mutations in S-gene so this test can accurately distinguish the new Stealth variant from standard Omicron. Ankündigung • Dec 01
Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant Seegene Inc. confirmed that its Allplex™ SARS-CoV-2 Master Assay is capable of detecting the Omicron's unique pattern of mutations. The well-established PCR-based test recognizes four SARS-CoV-2 genes and five notable mutations on the spike protein, all in a single test tube. This provides accurate results on whether a person is positive for COVID-19 and if they have the Omicron variant within 4 hours. To maximize its use, Seegene will support countries in need of tests, so they can rapidly detect cases of Omicron without the labor and equipment required for full genomic sequencing. The Allplex™ SARS-CoV-2 Master Assay simultaneously detects four wild-type SARS-CoV-2 genes (E gene, RdRP gene, N gene, and S gene) and five notable S-gene mutations: HV69/70 deletion, Y144 deletion, E484K, N501Y, and P681H. Since the latest variant Omicron contains HV69/70 deletion, N501Y, and P681H mutations, this CE-IVD marked test can detect Omicron. The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries. The process for identifying novel variants typically involves next-generation sequencing of the isolated virus, which would take a few days to get the complete result. For more rapid detection, Seegene's Allplex™ SARS-CoV-2 Master Assay can detect the variant in the very first stage of screening. Public health officials can then rapidly isolate and contact trace people who are infected with this variant of concern. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improved over the past week After last week's 15% share price gain to ₩62,700, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 611% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩33,148 per share. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩50,000, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 23x in the Biotechs industry in South Korea. Total returns to shareholders of 364% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩37,196 per share. Ankündigung • Sep 29
Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC Seegene Inc. is unveiling a fully automated PCR testing (MDx) system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September 26-30, 2021, in Atlanta, GA, USA. The AACC is a premier exposition for clinical laboratory products and services with 73 years of history. This global event invites players of major laboratory medicine community including 700 global IVD companies. Seegene also has participated in this event since 2007 along with other global IVD companies. During this event, Seegene will be unveiling AIOS - its first fully automated MDx system. AIOS provides high-throughput real-time PCR workflow starting from nucleic acid extraction, then, real-time PCR, and finally result interpretation. AIOS is fully automated syndromic MDx system designed in a modular concept while it compiles Seegene's cutting-edge high multiplex real-time PCR technologies. A noteworthy feature of AIOS is that its MDx system is composed of independent and detachable modules together with its proprietary SW architecture. Unlike others' single-body system, AIOS is designed with an extraction/liquid handler and PCR instrument being integrated with an in-house developed robotic arm module. Hospitals and laboratories can either purchase the full package of 'AIOS' system or integrate their existing instruments on site if they already have Seegene's liquid handler and real-time PCR instrument. Some of the other highlights include: 'high-throughput automated syndromic MDx system'. It also adopts a variety of Seegene's assays, that are currently available on the market, which allows for symptom-based tests. And finally, it can identify the exact cause of a specific symptom with a single tube, which will enable both cost- and time- effective tests. Therefore, Seegene added that AIOS will be affordable to small-to-medium sized hospitals due to its unique modular and assay features. Price Target Changed • Sep 08
Price target decreased to ₩89,000 Down from ₩116,750, the current price target is provided by 1 analyst. New target price is 41% above last closing price of ₩63,000. Stock is down 48% over the past year. Major Estimate Revision • Aug 19
Consensus EPS estimates increase to ₩9,305 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from ₩1.23b to ₩1.24b. EPS estimate increased from ₩7,365 to ₩9,305 per share. Net income forecast to shrink 28% next year vs 21% growth forecast for Biotechs industry in South Korea . Consensus price target down from ₩116,750 to ₩112,000. Share price fell 11% to ₩65,500 over the past week. Ankündigung • Jul 15
Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus Seegene Inc. has announced the launch of a new SARS-CoV-2 variant diagnostic test capable of screening newly emerging virus variants including the Delta and the Delta Plus that have become the dominant version of the virus circulating around the world. The company announced on June 30 that it has received the CE-IVD mark for its 'Allplex™ SARS-CoV-2 Variants II Assay,' a new lineup of the company's variant detection kits capable of detecting the key genetic mutations of SARS-CoV-2 variants such as L452R, W152C, K417T and K417N. In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California). While the number of daily new infections is growing exponentially, the launch of the new assay is expected to play an essential role in monitoring the spread of the Delta and Delta Plus variants that have been largely blamed for the bulk of new infections. Earlier this year, the World Health Organization (WHO) classified the Delta variant as the 'Variant of Concern' as the variant is expected to rapidly outcompete other variants. Also, the emergence of a new mutation on the spike protein of the Delta known as K417N has raised alarm globally, as it is known to be more contagious than the Delta and exhibit vaccine resistance. These super-contagious variants recently have become a global threat. In countries like the UK and Indonesia Delta is the dominant strain accounting for around 90% of new cases. Also, in other countries like the United States, although the variant only made up about 20% of infections, the number appears to be doubling every two weeks. Under such circumstances, the introduction of the 'Allplex™ SARS-CoV-2 Variants II Assay' is receiving much attention from around the world as the assay can screen both Delta and the Delta Plus variant as well as other major COVID-19 variants. The company also announced that it has successfully developed a research-use-only diagnostic tests, 'Allplex™ SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants. According to the company, the conjunction use of the two assays will allow researchers to accurately distinguish the Delta and Delta Plus variants from other genetic mutations. Ankündigung • Jun 30
Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021 Seegene Inc. introduced its new deployable container laboratory "MOBILE STATION", at the Medlab Middle East
2021, the medical laboratory and In Vitro Diagnostic exhibition which is taking place in Dubai
from June 21 to 24. Seegene's MOBILE STATION, an innovative laboratory-on-wheels facility, is designed to deploy the gold standard PCR testing solution to anywhere community-based testing is needed. While many countries around the world are planning to re-open their borders, schools, and public-use facilities, MOBILE STATION is considered an ideal option for conducting mass PCR testing in such locations. Also, MOBILE STATION can be mobilized anytime, allowing more people to utilize molecular diagnostics when needed. MOBILE STATION sets the new bar of PCR lab setting with its ability to deliver effective testing solutions to
anywhere testing is needed. PCR testing has been normally conducted only at fixed space due to concerns of
cross-contamination. However, MOBILE STATION, with Seegene's technology and know-how gained through operation of South Korea's large reference laboratory, has already minimized the overall risks of aerosol contamination posed in PCR process by installing Class 2 (A2) Bio-Safety Cabinet and negative pressure room.
From sample collection to automated interpretation of results, it offers streamlined and automated workflow
backed by the company's All-in-One platform thereby allowing equitable access to health care for the public.
Seegene'sAll-in-One platform, when fully utilized, can conduct up to 7500 tests per day with a turnaround time
of 3.5 hours. Seegene's pioneering concept of the mobile laboratory is expected to play a significant role in stopping the current pandemic since Seegene offers unparalleled PCR testing solution with its exclusive multiplex assays including Allplex SARS-CoV-2 Master Assay, a kit that simultaneously detects COVID-19 and multiple virus variants and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, a kit differentiates 8 target genes including Flu A, Flu B, RSV A/B and three different target genes of COVID-19. MOBILE STATION is also fully compatible with Seegene's more than 150 multiplex assay menus including tests for respiratory infectious pathogens, HPV, STI, and GI. Seegene also introduced 'Combo Swab', a self-administrable sample collection device. In comparison to nasopharyngeal swab, typically used in sampling for COVID-19 PCR testing, in which health care providers collect samples by inserting a swab deep inside nostrils, Combo Swab allows individuals to simply collect samples with two individual swabs through swirling around their nasal and oral cavity by two individual swabs without any discomfort. In addition, Combo Swab with dual sample collection showed the same accuracy compared to nasopharyngeal swab. Self-sample collection availability of Combo Swab along with provisional space scalability of MOBILE STATION enables mass testing to be proceed in a quicker time and more efficient manner than the conventional process. Valuation Update With 7 Day Price Move • Jun 22
Investor sentiment improved over the past week After last week's 16% share price gain to ₩74,700, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 37x in the Biotechs industry in South Korea. Total returns to shareholders of 394% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,727 per share. Price Target Changed • Jun 11
Price target decreased to ₩116,750 Down from ₩145,800, the current price target is an average from 2 analysts. New target price is 89% above last closing price of ₩61,900. Stock is up 11% over the past year. Ankündigung • May 24
Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants Seegene Inc. announced that against the backdrop of Seegene's 'Full Screening Solution' are the company's latest variant diagnostic tests, the AllplexTM SARS-CoV-2 Master Assay and AllplexTM SARS-CoV-2 Variants I Assay. The AllplexTM SARS-CoV-2 Master is an ideal way of screening for the COVID-19, as it provides results of whether a person is positive of the COVID-19 or even its variants. After an initial round of testing, Seegene's AllplexTM SARS-CoV-2 Variants I Assay will help identify multiple mutant variations in a single reaction. The AllplexTM SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes (E gene, RdRP gene, N gene and S gene) as well as five defined virus variants notably spotted in the most recognized lineages including B1.1.7, B.1.351, P.1 and B.1.1.207. Seegene's variant diagnostic test is the first such kind to simultaneously detect multiple coronavirus genes and differentiate virus variations, including those found to be more contagious and fatal. It's an ideal and an economic way of screening coronavirus genes as the pandemic continues to rage with both the wildtype and its virus variants. Valuation Update With 7 Day Price Move • May 04
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩83,400, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 32x in the Biotechs industry in South Korea. Total returns to shareholders of 423% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩117,790 per share. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment improved over the past week After last week's 27% share price gain to ₩169,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 30x in the Biotechs industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩226,835 per share. Reported Earnings • Mar 17
Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩1.13t (up ₩1.00t from FY 2019). Net income: ₩502.3b (up ₩475.6b from FY 2019). Profit margin: 45% (up from 22% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 133% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth. Ankündigung • Mar 03
Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its AllplexTM SARS-CoV-2/FluA/FluB/RSV Assay Seegene Inc. has submitted its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA). Seegene's Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is a real-time RT-PCR assay that can simultaneously detect and differentiate eight target genes, including Flu A, Flu B, RSV A/B and three different target genes of COVID-19 (S gene, RdRP gene and N gene). The assay also includes dual targets for internal control (endogenous and exogenous respectively) in the same reaction tube, also Seegene’s unique channel of allowing for verification of the whole test process, as well as proper sampling, without having to compromise the accuracy of test results. The Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is currently available in Europe and elsewhere around the world.